Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
You may also be interested in...
Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.
Singapore- and US-based rational antibody design venture closes major new financing to support progress of its novel pipeline, with its two lead assets set to enter the clinic shortly. CEO Piers Ingram talks to Scrip about plans and strategy.
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.